Replication cohort and meta-analysis results for replicated loci for proliferative lupus nephritis and end-stage renal disease in SLE
| Discovery cohort (Sweden) | Replication cohort (multiethnic)** | Meta-analysis†† | ||||||||||
| Locus | SNV | MAF | MAF | P value | OR (95% CI) | MAF | MAF | P value | OR (95% CI) | P value | OR | I2 % |
| Proliferative LN vs SLE-non-LN | pLN+ n=153 | LN- n=620 | pLN+ n=93 | LN- n=623 | ||||||||
| APOA1BP | rs942960 | 0.08 | 0.03 | 2.76E-05 | 3.23 (1.87 to 5.59) | 0.08 | 0.05 | 0.037 | 1.99 (1.04 to 3.8) | 1.16E-05 | 2.64 | 0 |
| APOA1BP | rs942961 | 0.08 | 0.03 | 2.76E-05 | 3.23 (1.87 to 5.59) | 0.08 | 0.05 | 0.037 | 1.99 (1.04 to 3.8) | 1.16E-05 | 2.64 | 0 |
| PRDM1 | rs1984224 | 0.25 | 0.38 | 6.14E-05 | 0.54 (0.4 to 0.73) | 0.25 | 0.31 | 0.036 | 0.66 (0.44 to 0.97) | 2.50E-05 | 0.58 | 0 |
| PRDM1 | rs6924535 | 0.26 | 0.38 | 5.08E-05 | 0.53 (0.39 to 0.72) | 0.25 | 0.30 | 0.029 | 0.65 (0.44 to 0.96) | 1.58E-05 | 0.59 | 0 |
| PRDM1 | rs535780 | 0.26 | 0.38 | 7.88E-05 | 0.54 (0.4 to 0.73) | 0.30 | 0.34 | 0.019 | 0.63 (0.43 to 0.93) | 3.19E-03 | 0.59 | 30 |
| ESRD vs SLE non-LN | ESRD+ n=35 | LN- n=620 | ESRD+ n=73 | LN- n=623 | ||||||||
| MERTK | rs72825639 | 0.13 | 0.02 | 7.84E-06 | 7.58 (3.12 to 18.43) | 0.05 | 0.03 | 0.044 | 2.57 (1.02 to 6.46) | 8.95E-07 | 5.50 | 0 |
| MERTK | rs56097910 | 0.13 | 0.02 | 9.52E-06 | 7.32 (3.03 to 17.68) | 0.05 | 0.03 | 0.043 | 2.59 (1.03 to 6.5) | 1.03E-06 | 5.40 | 0 |
| MERTK | rs72825650 | 0.13 | 0.02 | 9.49E-06 | 7.33 (3.03 to 17.68) | 0.05 | 0.03 | 0.043 | 2.59 (1.03 to 6.5) | 1.03E-06 | 5.40 | 0 |
*Multiethnic cohort, all ethnicities combined.
†Each replication population analysed separately by logistic regression, then included in a meta-analysis with the discovery cohort.
ESRD, end-stage renal disease; I2, I2-statistics for heterogeneity of studies; LN, lupus nephritis; MAF, minor allele frequency; pLN, proliferative LN.